Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, Clauditz TS, Grupp K, Minner S, Tsourlakis MC, Möller-Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Izbicki JR, Huland H, Schlomm T, Steurer S, Krech T, Lebok P. Wilczak W, et al. Carcinogenesis. 2017 Jan;38(1):19-27. doi: 10.1093/carcin/bgw116. Epub 2016 Nov 1. Carcinogenesis. 2017. PMID: 27803051
Deletion of 18q is a strong and independent prognostic feature in prostate cancer.
Kluth M, Graunke M, Möller-Koop C, Hube-Magg C, Minner S, Michl U, Graefen M, Huland H, Pompe R, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Büscheck F, Clauditz T, Wilczak W, Sauter G, Schlomm T, Simon R. Kluth M, et al. Oncotarget. 2016 Dec 27;7(52):86339-86349. doi: 10.18632/oncotarget.13404. Oncotarget. 2016. PMID: 27861151 Free PMC article.
Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M, Amschler NN, Galal R, Möller-Koop C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Steurer S, Krech T, Büscheck F, Clauditz TS, Beyer B, Wilczak W, Graefen M, Huland H, Minner S, Schlomm T, Sauter G, Simon R. Kluth M, et al. Oncotarget. 2017 Jan 3;8(1):379-392. doi: 10.18632/oncotarget.13425. Oncotarget. 2017. PMID: 27880722 Free PMC article.
High-Level γ-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer.
Melling N, Rashed M, Schroeder C, Hube-Magg C, Kluth M, Lang D, Simon R, Möller-Koop C, Steurer S, Sauter G, Jacobsen F, Büscheck F, Wittmer C, Clauditz T, Krech T, Tsourlakis MC, Minner S, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Wilczak W. Melling N, et al. Int J Mol Sci. 2017 Jan 29;18(2):286. doi: 10.3390/ijms18020286. Int J Mol Sci. 2017. PMID: 28146062 Free PMC article.
Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.
Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl HU, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki JR, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, Wilczak W. Burdelski C, et al. Oncotarget. 2017 May 9;8(19):31494-31508. doi: 10.18632/oncotarget.16357. Oncotarget. 2017. PMID: 28415558 Free PMC article.
Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion.
Juhnke M, Heumann A, Chirico V, Höflmayer D, Menz A, Hinsch A, Hube-Magg C, Kluth M, Lang DS, Möller-Koop C, Sauter G, Simon R, Beyer B, Pompe R, Thederan I, Schlomm T, Luebke AM. Juhnke M, et al. Mol Carcinog. 2017 Sep;56(9):2135-2145. doi: 10.1002/mc.22670. Epub 2017 May 22. Mol Carcinog. 2017. PMID: 28467610
High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer.
Burdelski C, Shihada R, Hinsch A, Angerer A, Göbel C, Friedrich E, Hube-Magg C, Burdak-Rothkamm S, Kluth M, Simon R, Möller-Koop C, Sauter G, Büscheck F, Wittmer C, Clauditz TS, Krech T, Tsourlakis MC, Minner S, Graefen M, Schlomm T, Wilczak W, Jacobsen F. Burdelski C, et al. Prostate. 2017 Nov;77(15):1528-1538. doi: 10.1002/pros.23431. Epub 2017 Sep 19. Prostate. 2017. PMID: 28929505
High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer.
Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M, Minner S, Möller-Koop C, Graefen M, Heinzer H, Tsourlakis MC, Wilczak W, Wittmer C, Jacobsen F, Huland H, Simon R, Schlomm T, Sauter G, Steurer S, Lebok P, Hinsch A. Heumann A, et al. BMC Cancer. 2018 Jan 5;18(1):37. doi: 10.1186/s12885-017-3956-3. BMC Cancer. 2018. PMID: 29304771 Free PMC article.
Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.
Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz TS, Krech T, Tsourlakis MC, Schroeder C. Hinsch A, et al. World J Urol. 2018 Jun;36(6):877-882. doi: 10.1007/s00345-018-2225-7. Epub 2018 Feb 9. World J Urol. 2018. PMID: 29427004
45 results